PR92986

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

SAN DIEGO and BENGALURU, India, November 11, 2021 /PRNewswire＝KYODO JBN/ -

    Jubilant Biosys Limited announced today, an expansion of its facilities to

support its discovery chemistry and in-vitro ADME Service offerings. Jubilant

Biosys provides services for Turning Point Therapeutics Inc. for multiple small

molecule oncology research programs. Turning Point is a precision oncology

company developing next-generation therapies that target genetic drivers of

cancer.

    Services for Turning Point Therapeutics Inc. will be conducted out of

Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation

Research Center (CIRC) in Greater Noida, India. It's Chemistry Innovation

Research Center has an initial capacity of 500 FTEs enabling higher operational

performance for discovery chemistry services and also rapid turn-around of

in-vitro ADME data for client projects.

    Commenting on this expansion, Giuliano Perfetti, Chief Executive Officer,

Jubilant Biosys Limited said, "We are delighted to unveil our newly built

Chemistry Innovation Research Center, Greater Noida for Turning Point's and our

other clients' project needs and we are looking forward to accelerating their

programs through this site."

    "We are excited to continue our relationship with Jubilant Biosys Limited as

they start using their CIRC. They continue to provide skilled contract services

for challenging synthetic chemistry projects while realizing the importance of

short cycle times to deliver and provide critical in-vitro ADME data for our

growing portfolio," said Siegfried Reich, Ph.D., chief scientific officer,

Turning Point Therapeutics.

    About Jubilant Biosys Limited

    Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an

integrated global pharmaceutical company, has presence in Bengaluru and Noida in

India. Jubilant Biosys offers contract research & development services for

global pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in

functional services in chemistry including - computational, medicinal/synthetic

chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in

biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology

and Toxicology. Further, Jubilant Biosys has integrated discovery expertise with

a track record of working on over 80 programs in multiple therapeutic areas

including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation,

CNS and expanding into Rare Diseases. For more information, please visit:

www.jubilantbiosys.com

    About Turning Point Therapeutics

    Turning Point Therapeutics is a clinical-stage precision oncology company

with a

pipeline of internally discovered investigational drugs designed to address key

limitations of existing cancer therapies. The company's lead drug candidate,

repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK

oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

Repotrectinib, which is being studied in a registrational Phase 2 study in

adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity

and durable responses among kinase inhibitor treatment-na�ve and pre-treated

patients. The company's pipeline of drug candidates also includes elzovantinib,

targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of

patients with advanced or metastatic solid tumors harboring genetic alterations

in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of

patients with advanced or metastatic solid tumors harboring genetic alterations

in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in

a Phase 1/2 trial of previously treated patients with ALK-positive advanced or

metastatic non-small cell lung cancer. The company is driven to develop

therapies that mark a turning point for patients in their cancer treatment. For

more information, visit www.tptherapeutics.com.

    About Jubilant Pharmova Limited

    Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a

company

engaged in Pharmaceuticals, Contract Research and Development Services and

Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant

Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of

Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy

Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile

products, APIs and Solid Dosage Formulations through six manufacturing

facilities that cater to all the regulated market including USA, Europe and

other geographies. Jubilant Biosys Limited provides contract research and

development services through two world class research centers in Bangalore and

Noida in India. Jubilant Pharmova Limited has a team of over 6,000 multicultural

people across the globe. The Company is well recognized as a 'Partner of Choice'

by leading pharmaceuticals companies globally. For more information, please

visit: www.jubilantpharmova.com

    Business Development Contact:

    Ravichandran S

    bd@jubilantbiosys.com

    Logo: https://mma.prnewswire.com/media/821405/Jubilant_Biosys_Logo.jpg

    Source: Jubilant Biosys Limited